Literature DB >> 10640282

Chemically modified oligonucleotides exhibit decreased immune stimulation in mice.

S Henry1, K Stecker, D Brooks, D Monteith, B Conklin, C F Bennett.   

Abstract

Phosphorothioate oligodeoxynucleotides produce splenomegaly and mononuclear cell infiltrates in multiple organs in mice after repeated i.v. administration. Several phosphorothioate oligodeoxynucleotides were studied to better understand the basis of immunostimulatory properties of these molecules in mice and to study the effects of chemically modified oligonucleotides. Chemical modifications examined included 5-methyl cytosine and 2'-methoxyethoxy substituents. Male mice (six per group) were treated with oligonucleotide concentrations of 0, 2, 10, or 50 mg/kg by i.v. injection every other day for 14 days. Immune stimulation was assessed 24 h after the last dose by measuring spleen weight, or histologic and immunohistochemical examination of liver and kidney. Immune stimulation was dose-dependent for the phosphorothioate oligodeoxynucleotides studied, but potency varied as a function of sequence. Results from this study reveal that there is a close correlation between the extent of splenomegaly and other evidence of immune stimulation, such as the severity of cell infiltrates in liver and kidney in mice. Immunohistochemical analysis indicated that cell infiltrates in liver and kidney were primarily mononuclear cells associated with increased expression of the endothelial-leukocyte cellular adhesion molecule intracellular adhesion molecule-1 and the cytokine interleukin-6. Immune stimulation was markedly decreased with oligonucleotides containing the 5-methyl cytosine and further decreased by 2'-methoxyethoxy modifications. Administration of these modified oligonucleotides to mice did not produce splenomegaly even at the 50-mg/kg dose, and only produced minimal cell infiltrates despite the presence of comparable or greater tissue oligonucleotide concentrations. Thus, chemical modifications appeared to increase the tolerability profile for these compounds that are representative of the second generation of antisense oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10640282

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  35 in total

1.  Inhibition of telomerase by 2'-O-(2-methoxyethyl) RNA oligomers: effect of length, phosphorothioate substitution and time inside cells.

Authors:  A N Elayadi; A Demieville; E V Wancewicz; B P Monia; D R Corey
Journal:  Nucleic Acids Res       Date:  2001-04-15       Impact factor: 16.971

Review 2.  Oligonucleotide therapeutic approaches for Huntington disease.

Authors:  Dinah W Y Sah; Neil Aronin
Journal:  J Clin Invest       Date:  2011-02-01       Impact factor: 14.808

3.  Hybrid Mouse Diversity Panel Identifies Genetic Architecture Associated with the Acute Antisense Oligonucleotide-Mediated Inflammatory Response to a 2'-O-Methoxyethyl Antisense Oligonucleotide.

Authors:  Elaine Pirie; Patrick Cauntay; Wuxia Fu; Shayoni Ray; Calvin Pan; Aldonis J Lusis; Jill Hsiao; Sebastien A Burel; Padma Narayanan; Rosanne M Crooke; Richard G Lee
Journal:  Nucleic Acid Ther       Date:  2019-08-01       Impact factor: 5.486

4.  RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1.

Authors:  Johanna E Lee; C Frank Bennett; Thomas A Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-27       Impact factor: 11.205

5.  Impact of dosing regimen of custirsen, an antisense oligonucleotide, on safety, tolerability and cardiac repolarization in healthy subjects.

Authors:  Laura Rabinovich-Guilatt; Anna Elgart; Lavi Erisson; Sandra K Willsie; Shoshi Tessler; Ofra Barnett-Griness; Amitkumar Pande; Ofer Spiegelstein
Journal:  Br J Clin Pharmacol       Date:  2015-06-22       Impact factor: 4.335

Review 6.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin Gleave; Hideaki Miyake
Journal:  World J Urol       Date:  2005-01-26       Impact factor: 4.226

7.  Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis.

Authors:  Katey J Rayner; Frederick J Sheedy; Christine C Esau; Farah N Hussain; Ryan E Temel; Saj Parathath; Janine M van Gils; Alistair J Rayner; Aaron N Chang; Yajaira Suarez; Carlos Fernandez-Hernando; Edward A Fisher; Kathryn J Moore
Journal:  J Clin Invest       Date:  2011-06-06       Impact factor: 14.808

8.  Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.

Authors:  Kenneth T Luu; Erin S Morgan; Sanjay Bhanot; Richard Geary; Anne Smith; Claudette Bethune; Lynnetta Watts; Scott Henry; Yanfeng Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-01-28       Impact factor: 2.745

9.  Identification and functional validation of PNAs that inhibit murine CD40 expression by redirection of splicing.

Authors:  Andrew M Siwkowski; Leila Malik; Christine C Esau; Martin A Maier; Edward V Wancewicz; Klaus Albertshofer; Brett P Monia; C Frank Bennett; Anne B Eldrup
Journal:  Nucleic Acids Res       Date:  2004-05-17       Impact factor: 16.971

10.  Toxicological and pharmacokinetic properties of chemically modified siRNAs targeting p53 RNA following intravenous administration.

Authors:  James D Thompson; Douglas J Kornbrust; Jeffrey W-D Foy; Elisabeth C R Solano; David J Schneider; Elena Feinstein; Bruce A Molitoris; Shai Erlich
Journal:  Nucleic Acid Ther       Date:  2012-08       Impact factor: 5.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.